This course covers the regulatory framework governing artificial

intelligence and machine learning in pharmaceutical GMP

manufacturing from the FDA FRAME Initiative through to the

Purolea warning letter, the ISPE GAMP AI Guide and FDA's

planned 2026 AI/ML Quality Considerations guidance.

The course opens with FDA's unambiguous regulatory position.

Existing CGMP regulations apply fully to AI systems in

pharmaceutical manufacturing now. There is no AI-specific

exemption. 21 CFR 211.68 requires that electronic equipment

used in manufacturing be validated for its intended use an

AI model used in a quality or manufacturing decision is

electronic equipment under 211.68. The CSA final guidance

(September 2025) explicitly includes AI and machine learning

systems within scope.

The FDA regulatory timeline is covered in full from the

CDER FRAME Initiative in 2021, the landmark AI in Drug

Manufacturing discussion paper in March 2023, the January

2025 draft guidance on AI to support regulatory

decision-making, the joint FDA and EMA Guiding Principles of

Good AI Practice published January 2026 and the planned 2026

AI/ML Quality Considerations in Pharmaceutical Manufacturing

guidance on FDA's formal guidance agenda.

The April 2026 Purolea Pharmaceuticals warning letter is

examined in depth the first FDA enforcement action citing AI

misuse in pharmaceutical manufacturing. Three specific

findings are covered: AI-generated batch records accepted

without human verification, AI-generated SOPs contradicting

validated process parameters, and absence of AI system

validation under 21 CFR 211.68. The course explains why the

absence of validation was the foundational failure that

enabled the other two findings.

The four AI application categories in pharmaceutical

manufacturing are covered process monitoring and control,

predictive maintenance, environmental monitoring and

contamination detection, and quality system and document

management with their respective risk profiles and

validation expectations.

AI validation under CSA principles is covered in three steps

intended use assessment driving the scope of assurance

activities, risk-based assurance planning including scripted

versus unscripted testing, and lifecycle and change control

requirements including model drift monitoring, vendor-pushed

update assessment and training data integrity.

The ISPE GAMP AI Guide (July 2025) four-category framework

is covered in depth informative AI, assistive AI, autonomous

AI and independent AI including the critical controls for

each category and how generative AI used in CGMP documentation

falls into the highest risk category regardless of human

approval of the output.

The course concludes with five immediate actions every site

should take before the 2026 guidance is finalised and the

warning signs FDA inspectors are increasingly alert to in AI

governance programmes.

Suitable for: QA managers and specialists, validation

engineers and scientists, IT teams managing GxP systems,

laboratory systems administrators, manufacturing operations

managers and all personnel whose roles involve implementing,

reviewing or approving AI or machine learning tools in

any GxP-regulated activity.

Approx. 30 minutes | 5 assessment questions | Certificate

on completion

Sources: 21 CFR 211.68 | CSA Final Guidance September 2025 |

FDA FRAME Initiative | FDA AI Discussion Paper March 2023 |

FDA Draft Guidance January 2025 | ISPE GAMP AI Guide July

2025 | Purolea Warning Letter April 2026 | fda.gov